High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors

PLoS Pathogens

Volumn 5, Issue 10, 2009, Pages

  Christophe, Thierry ^a   Jackson, Mary ^b   Hee, Kyoung Jeon ^a   Fenistein, Denis ^c   Contreras Dominguez, Monica ^d   Kim, Jaeseung ^e   Genovesio, Auguste ^c   Carralot, Jean Philippe ^d   Ewann, Fanny ^d   Kim, Eun Hye ^d   Lee, Sae Yeon ^e   Kang, Sunhee ^e   Seo, Min Jung ^e   Eun, Jung Park ^e   Škovierová, Henrieta ^b   Pham, Ha ^b   Riccardi, Giovanna ^f   Youn, Nam Ji ^a   Marsollier, Laurent ^g   Kempf, Marie ^g   Joly Guillou, Marie Laure ^g   Oh, Taegwon ^h   Won, Kyung Shin ^h   No, Zaesung ^e   Nehrbass, Ulf ^a   Brosch, Roland ⁱ   Cole, Stewart T ^j   Brodin, Priscille ^d,i   more..

^a Screening Technologies and Pharmacology   (South Korea)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c Image Mining Group   (South Korea)

^d Institute Pasteur Korea   (South Korea)

^e Institute Pasteur Korea   (South Korea)

^f UNIVERSITY OF PAVIA   (Italy)

^g UNIVERSITÉ D'ANGERS   (France)

^h International Tuberculosis Research Center   (South Korea)

ⁱ INSTITUT PASTEUR   (France)

^j EPFL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; ANTIINFECTIVE AGENT; ARABINOGALACTAN; AX 20017; BACTERIAL ENZYME; BENZAMIDE DERIVATIVE; DECAPRENYL PHOSPHO ARABINOSE; DECAPRENYL PHOSPHORIBOSE 2' EPIMERASE; DINITROBENZAMIDE DERIVATIVE; EPIMERASE; ETHAMBUTOL; ETHIONAMIDE; FUSIDIC ACID; ISONIAZID; LEVOFLOXACIN; LIPID; LIPOARABINOMANNAN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ISOMERASE;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; AUTOMATION; BACTERIAL GROWTH; CATALYSIS; CELL ASSAY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; HOST CELL; HUMAN; HUMAN CELL; LIPOGENESIS; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; ANIMAL; CELL CULTURE; CELL GROWTH; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG EFFECT; ENZYMOLOGY; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PRINCIPAL COMPONENT ANALYSIS; REPRODUCIBILITY; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

BACILLI (CLASS); MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; BENZAMIDES; CELL GROWTH PROCESSES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MYCOBACTERIUM TUBERCULOSIS; PRINCIPAL COMPONENT ANALYSIS; RACEMASES AND EPIMERASES; REPRODUCIBILITY OF RESULTS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS;

EID: 73649143180     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000645     Document Type: Article

References (37)

1. Kumar V, Abbas K, Fausto N, Mitchell RN Robbins Basic Pathology (8th ed.). pp 516-522.
2. Armstrong JA, Hart PD (1971) Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med 134: 713-740.
3. Bermudez LE, Goodman J (1996) Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect Immun 64: 1400-1406.
4. Warner DF, Mizrahi V (2007) The survival kit of Mycobacterium tuberculosis. Nat Med 13: 282-284.
5. Neyrolles O, Hernandez-Pando R, Pietri-Rouxel F, Fornes P, Tailleux L, et al. (2006) Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS ONE 1: e43. doi:10.1371/journal.pone.0000043.
6. Tailleux L, Neyrolles O, Honore-Bouakline S, Perret E, Sanchez F, et al. (2003) Constrained intracellular survival of Mycobacterium tuberculosis in human dendritic cells. J Immunol 170: 1939-1948.
7. Rohde KH, Abramovitch RB, Russell DG (2007) Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. Cell Host Microbe 2: 352-364.
8. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, et al. (2003) Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J Exp Med 198: 693-704.
9. van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, et al. (2007) M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129: 1287-1298.
10. Young DB, Perkins MD, Duncan K, Barry CE, 3rd (2008) Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest 118: 1255-1265.
11. Balganesh TS, Alzari PM, Cole ST (2008) Rising standards for tuberculosis drug development. Trends Pharmacol Sci 29: 576-581.
12. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40.
13. Fenistein D, Lenseigne B, Christophe T, Brodin P, Genovesio A (2008) A fast, fully automated cell segmentation algorithm for high-throughput and highcontent screening. Cytometry A 73: 958-964.
14. Moon H, Genovesio A. IM., a Computing Approach for Image Mining of High Throughput-High Content Screening; Sept. 29 2008-Oct. 1 2008 September 29-October 1; Tsukuba, Japan. IEEE Computer Society. pp 334-339.
15. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966.
16. Hartkoorn RC, Chandler B, Owen A, Ward SA, Bertel Squire S, et al. (2007) Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis (Edinb) 87: 248-255.
17. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, et al. (2007) Low-oxygenrecovery assay for high-throughput screening of compounds against non replicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 51: 1380-1385.
18. Wolucka BA, McNeil MR, de Hoffmann E, Chojnacki T, Brennan PJ (1994) Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. J Biol Chem 269: 23328-23335.
19. Wolucka BA (2008) Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy. Febs J 275: 2691-2711.
20. Mikusova K, Huang H, Yagi T, Holsters M, Vereecke D, et al. (2005) Decaprenylphosphoryl arabinofuranose, the donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J Bacteriol 187: 8020-8025.
21. Makarov V, Manina G, Mikusova K, Mollmann U, Ryabova O, et al. (2009) Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis. Science.
22. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, et al. (2009) A replication clock for Mycobacterium tuberculosis. Nat Med 15: 211-214.
23. Puissegur MP, Botanch C, Duteyrat JL, Delsol G, Caratero C, et al. (2004) An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells. Cell Microbiol 6: 423-433.
24. Davis JM, Ramakrishnan L (2009) The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 136: 37-49.
25. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
26. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, et al. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397-2405.
27. Barry CE, 3rd, Slayden RA, Sampson AE, Lee RE (2000) Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochem Pharmacol 59: 221-231.
28. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544.
29. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77-84.
30. Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P, et al. (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322: 1392-1395.
31. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 46: 3-26.
32. Abadie V, Badell E, Douillard P, Ensergueix D, Leenen PJ, et al. (2005) Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 106: 1843-1850.
33. Palomino JC, Martin A, Camacho M, Guerra H, Swings J, et al. (2002) Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 46: 2720-2722.
34. Brodin P, Majlessi L, Marsollier L, de Jonge MI, Bottai D, et al. (2006) Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. Infect Immun 74: 88-98.
35. Scherman MS, Kalbe-Bournonville L, Bush D, Xin Y, Deng L, et al. (1996) Polyprenylphosphate-pentoses in mycobacteria are synthesized from 5-phosphoribose pyrophosphate. J Biol Chem 271: 29652-29658.
36. Mikusova K, Slayden RA, Besra GS, Brennan PJ (1995) Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother 39: 2484-2489.
37. Rousseau C, Sirakova TD, Dubey VS, Bordat Y, Kolattukudy PE, et al. (2003) Virulence attenuation of two Mas-like polyketide synthase mutants of Mycobacterium tuberculosis. Microbiology 149: 1837-1847.